This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow This Policy is No Longer Valid.
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Related Collections
Right arrow Office Practice
Right arrowRelated AAP Red Book topics:
Lyme Disease (Lyme borreliosis,...

PEDIATRICS Vol. 105 No. 1 January 2000, pp. 142-147

AMERICAN ACADEMY OF PEDIATRICS:
Prevention of Lyme Disease

Committee on Infectious Diseases

Lyme disease is currently the most frequently reported vector-borne illness in the United States, accounting for more than 95% of such cases. The purpose of this report is to provide recommendations for preventing Lyme disease, including the use of Lyme disease vaccine. Individuals can reduce their risk of Lyme disease by avoiding tick-infested habitats when in endemic areas. If exposure to tick-infested habitats cannot be avoided, individuals may reduce their risk of infection by using repellents, wearing protective clothing, and regularly checking for and removing attached ticks. Morbidity from Lyme disease can be reduced significantly by detecting and treating the infection in its early stages; early and appropriate treatment almost always results in a prompt and uncomplicated cure. A Lyme disease vaccine (LYMErix, SmithKline Beecham, Collegeville, PA) was licensed by the US Food and Drug Administration on December 21, 1998, for persons 15 to 70 years of age. This vaccine seems to be safe and effective, but whether its use is cost-effective has yet to be clearly established. Use of this vaccine causes false-positive enzyme immunoassay results for Lyme disease. Lyme disease can be diagnosed in vaccinated persons by immunoblot testing. Decisions about the use of this vaccine should be based on an assessment of a person's risk as determined by activities and behaviors relating to tick exposure in endemic areas. This vaccine should be considered an adjunct to, not a replacement for, the practice of personal protective measures against tick exposure and the early diagnosis and treatment of Lyme disease.

.




This article has been cited by other articles:


Home page
 Scand J Public HealthHome page
L. Stjernberg and J. Berglund
Tick prevention in a population living in a highly endemic area
Scand J Public Health, December 1, 2005; 33(6): 432 - 438.
[Abstract] [PDF]

Home page
 PediatricsHome page
Committee on School Health, Section on School Heal
Health Appraisal Guidelines for Day Camps and Resident Camps
Pediatrics, June 1, 2005; 115(6): 1770 - 1773.
[Abstract] [Full Text] [PDF]

Home page
 Red BookHome page
Lyme Disease (Borrelia burgdorferi Infection)
Red Book, January 1, 2003; 2003(1): 407 - 411.
[Full Text]

Home page
 Clin. Microbiol. Rev.Home page
P. H. Dennehy
Active Immunization in the United States: Developments over the Past Decade
Clin. Microbiol. Rev., October 1, 2001; 14(4): 872 - 908.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
H. M. Feder and J. MD
Lyme Disease Vaccine: Good for Dogs, Adults, and Children?
Pediatrics, June 1, 2000; 105(6): 1333 - 1334.
[Full Text]